Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

NCT02200614 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT02200614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02200614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
September 12, 2014
Completion date
June 14, 2021
Enrollment
1,509 (actual)
Sites
404

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant, prostate cancer non-metastatic